Study of AMG531(Romiplostim) in Patients With Aplastic Anemia
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the hematological responses based on the response assessment criteria when AMG531
is subcutaneous (SC)-administered with anti-human thymocyte immunoglobulin (ATG) +
ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were
previously untreated with immunosuppressive therapy.